Alberta Is Second Canadian Province To Switch To Biosimilars
Follows British Columbia Switching Program That Began This Year
Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.
You may also be interested in...
Further Canadian provinces should follow British Columbia and Alberta by adopting biosimilar switching programs, Biosimilars Canada has urged, in the wake of the latest expansion of the British Columbia program to cover adalimumab.
British Columbia has expanded its biosimilar switching program to cover patients being treated with Humira in the Canadian province.
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.